UCLA Research Brief A new study led by UCLA investigators shows that Verbal Reaction Time (VRT), the amount of time it takes a person to respond verbally, can be a marker of sleepiness in older adults. The study, which measured participants’ voice data through standardized cognitive assessments, show how VRT […]
Tag: EXCESSIVE DAYTIME SLEEPINESS
Nap Roulette
My family loves to play games. One of the first things my husband and I bonded over was board games, and we passed that love of games to our children. As a family, we enjoy playing board games like Settlers of Catan and Carcassonne and card games like Dominion and […]
Excessive Daytime Sleepiness is Associated with Mortality in Middle-Aged Women
A new study to be presented at the SLEEP 2025 annual meeting found that excessive daytime sleepiness is associated with higher odds of all-cause mortality in middle-aged women but not in younger or older women. Results show that the adjusted odds of all-cause mortality were 16% higher in women between […]
Harmony Strengthens Patent With ANDA Settlement
Harmony Biosciences Holdings, Inc., today announced a settlement agreement with Lupin Limited, resolving the patent infringement litigation related to Lupin’s Abbreviated New Drug Application (ANDA) for a generic version of WAKIX® (pitolisant hydrochloride). As part of the agreement, litigation in the United States District Court for the District of Delaware will […]
Avadel Pharmaceuticals Presents New Data on LUMRYZ ER at SLEEP 2025
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 […]
The Diagnostic Journey for Narcolepsy
In previous editions, we’ve talked a lot about how diagnosis is only the first part of the journey with narcolepsy. It’s true that there are many pieces to managing the disorder that follow, but that diagnosis is something we really want to hone in on in this edition. The information […]
Jazz Pharmaceuticals to Showcase Research Demonstrating Treatment Benefits of Xywav at AAN
Jazz Pharmaceuticals plc announced that seven abstracts from across its neuroscience portfolio will be featured at the 77th Annual American Academy of Neurology Meeting (AAN) being held April 5-9, 2025, in San Diego. Data presented at the meeting includes an updated presentation of top-line results of the open-label, single-arm, Phase 4 DUET (Develop hypersomnia Understanding by Evaluating […]
Promising Results for Pitolisant in Prader-Willi Syndrome
Harmony Biosciences Holdings, Inc. announced the presentation of new secondary endpoint data, including improvements in behavioral disturbances, from its Phase 2 signal-detection study evaluating pitolisant for the treatment of excessive daytime sleepiness (EDS) in Prader-Willi syndrome (PWS) at the 2023 Foundation for Prader-Willi Research (FPWR) Symposium and Family Conference. The […]
New Clinical Guideline Recommendations for Sleep Disorders that Cause Excessive Sleepiness
A new clinical practice guideline developed by the American Academy of Sleep Medicine provides recommendations for the treatment of central disorders of hypersomnolence. These sleep disorders cause excessive sleepiness despite a sufficient amount of nocturnal sleep. The guideline, available online as an accepted paper in the Journal of Clinical Sleep Medicine, […]
Jazz Presents Phase 3 Results of Xywav in Adults with Idiopathic Hypersomnia
Jazz Pharmaceuticals plc has announced positive results from the Phase 3 study of XywavTM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting. The presentation will further […]













